日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial

在中国晚期胰腺腺癌患者中,NALIRIFOX 对比吉西他滨联合白蛋白紫杉醇:一项随机、开放标签的 II 期试验

Gao, Chuntao; Zhang, Yanqiao; Qu, Xiujuan; Chen, Xingyun; Zhang, Jingdong; Wu, Heshui; Sun, Meili; Zha, Yong; Wang, Junbin; Wang, Yusheng; Li, Zhihua; Gao, Jinghua; Lin, Rongbo; Zang, Aimin; Zhang, Huiqing; Yuan, Xianglin; Du, Chengyou; Zhao, Jun; Yang, Yongsheng; Shi, Xuetao; Cheng, Wei; Wang, Bangmao; Wu, Shikai; Zhao, Tiansuo; Wang, Jian; Gao, Song; Wang, Xiuchao; Ma, Weidong; Liu, Rui; Shi, Yehui; Liu, Yanping; Xie, Yijiao; Niu, Miao; Zhao, Fuchen; Yu, Jun; Hao, Jihui

HIF-1α suppresses SNPH expression to facilitate liver metastasis of colorectal cancer through regulating mitochondrial dynamics and filopodia formation.

HIF-1α抑制SNPH表达,通过调节线粒体动力学和丝状伪足的形成,促进结直肠癌的肝转移。

Zhan Lei, Li Xiaoxi, Li Xiaoyan, Fei Qian, Jin Yue, Yu Jiaxing, Tian Luyao, Li Feifei, Li Chunning, Dong Qian, Zhang Yong, Sun Shulan, Zhang Jingdong

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer

加索拉西布治疗KRAS G12C突变晚期胰腺癌患者的疗效和安全性

Yamamoto, Noboru; Yan, Dong; Ganju, Vinod; Hou, Xinfang; Pan, Hongming; Shan, Jianzhen; Wang, Liwei; Kim, Sang-We; Richardson, Gary; Sanborn, Rachel E; Zhang, Jingdong; Xiang, Ziyong; Wang, Wenjia; Shi, Zhe; Zhang, Ling; Wang, Yaolin; Xu, Rui-Hua

Case Report: The diagnostic and therapeutic crossroads: when myelofibrosis transforms into mixed phenotype acute leukemia

病例报告:诊断与治疗的十字路口:骨髓纤维化转化为混合表型急性白血病

Liu, Yanquan; Zhang, Jingdong; Du, Xiangzhou; Liao, Lihong

Bismuth-Based Materials as Solar-Driven Photo(Electro)Catalysts for Environmental Remediation

铋基材料作为太阳能驱动的光(电)催化剂用于环境修复

Ashraf, Muhammad; Guo, Jiang; Yan, Kai; Zhang, Jingdong

Monetary evaluation of quality-adjusted life year in patients with malignant tumor in China: Willingness-to-pay analysis

中国恶性肿瘤患者质量调整生命年货币评估:支付意愿分析

Huang, Li; Peng, Xiaochen; Zhang, Jingdong; Sun, Lihua

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Finotonlimab(PD-1抑制剂)联合贝伐单抗(贝伐单抗生物类似药)作为晚期肝细胞癌的一线治疗方案:一项随机2/3期试验

Zhao, Chuanhua; Zhang, Yanqiao; Wang, Gang; Zheng, Jinfang; Chen, Weiqing; Lu, Zheng; Zhuang, Li; Gu, Shanzhi; Han, Lei; Zheng, Zhendong; Yu, Zujiang; Yang, Yongsheng; Sun, Hongmei; Wei, Xiaoyong; Cheng, Ying; Lin, Hailan; Zhu, Bo; Wu, Guicheng; Lei, Kaijian; Wang, Wei; Wang, Yuwen; Chen, Kehe; Xu, Ximing; Zheng, Cuiping; Bi, Yanzhi; Ding, Sijuan; Zhang, Jingdong; Li, Wei; Liu, Hailong; Wang, Jun; Liu, Xianling; Du, Yangfeng; Cai, Lianming; Wang, Jingran; Luo, Zhanxiong; Xing, Baocai; Shen, Jie; Yang, Lin; Wu, Jianbing; Jiang, Ou; Peng, Zhigang; Liu, Xiuli; Cao, Bangwei; Shen, Liangfang; Xu, Aibing; Li, Aimin; Chen, Shaojun; Fu, Ting; Chen, Jian; Jin, Chuan; Zhang, Lei; Lv, Jun; Zhang, Chengwu; Zhang, Xiaoman; Wang, Yu; Su, Huo; Zhou, Qiang; Gai, Wenlin; Xie, Liangzhi; Xu, Jianming

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

在一项针对携带 KRAS G12C 突变的晚期实体瘤患者的 II 期临床试验中,KRAS G12C 抑制剂 Garsorasib 联合或不联合 EGFR 抗体西妥昔单抗,用于治疗结直肠癌患者。

Ruan, Dan-Yun; Wu, Hao-Xiang; Xu, Ye; Munster, Pamela N; Deng, Yanhong; Richardson, Gary; Yan, Dong; Lee, Myung-Ah; Lee, Keun-Wook; Pan, Hongming; Hager, Steven; Li, Xingya; Wei, Shaozhong; Hou, Xinfang; Underhill, Craig; Millward, Michael; Nordman, Ina; Zhang, Jingdong; Shan, Jianzhen; Han, Guohong; Grewal, Jaspreet; Gadgeel, Shirish M; Sanborn, Rachel E; Huh, Seok Jae; Hu, Xiaohua; Zhang, Yihong; Xiang, Ziyong; Luo, Laisheng; Xie, Xiaoxi; Shi, Zhe; Wang, Yaolin; Zhang, Ling; Wang, Feng; Xu, Rui-Hua

Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01)

安贝尼单抗联合化疗治疗既往接受过含曲妥珠单抗治疗失败的 HER2 阳性胃癌或胃食管交界处癌患者:一项多中心 II 期研究 (KC-WISE 01)

Zhao, Chuanhua; Zhao, Jun; Chen, Yigui; Liu, Bo; Du, Yangfeng; Li, Chenglin; Zhang, Jingdong; Yang, Mudan; Liu, Ying; Bai, Yuxian; Li, Suyi; Zhang, Ruixing; Ning, Fangling; Liu, Yanping; Zou, Kai; Zhang, Qi; Xie, Yijiao; An, Yuping; Xu, Jianming

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors

M701(一种抗EpCAM × 抗CD3双特异性抗体)的研发和临床试验:一种针对晚期实体瘤引起的恶性腹水的靶向腹腔内疗法

Liu, Rongrui; Lin, Rongbo; Li, Ning; Li, Guiling; Zhang, Tao; Zhao, Jun; Li, Jiayi; Sun, Meili; Wang, Ke; An, Hanxiang; Zhang, Weijie; Xu, Huiting; Zeng, Shan; Zhang, Mingjun; Duan, Wei; Bai, Yuxian; Zhang, Jingdong; Tian, He; Yin, Fei; Kang, Yu; Xu, Qi; Xu, Nong; Deng, Yanhong; Chen, Qing; Li, Yongqiang; Yang, Hongying; Su, Fang; Xiao, Zhenghong; Xiang, Xiaojun; Zhou, Pengfei; Huang, Shaoyi; Zhang, Jing; Xu, Jianming